Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Vertex Pharmaceuticals Incorporated”

980 pharma patents match "Vertex Pharmaceuticals Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 980
Index total 30,257
Page 3 / 41

Quick answer

This filtered view shows 980 pharmaceutical patents matching "Vertex Pharmaceuticals Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

980 results for “Vertex Pharmaceuticals Incorporated” · 30,257 patents in full index Clear search

  1. US 11945795

    Islet cell manufacturing compositions and methods of use

    Vertex Pharmaceuticals Incorporated · Granted Apr 2, 2024 · Expires Mar 28, 2044

    granted

  2. US 11919887

    Substituted tetrahydrofurans as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted

  3. US 11884672

    Modulators of alpha-1 antitrypsin

    Vertex Pharmaceuticals Incorporated · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted

  4. US 11873300

    Crystalline forms of CFTR modulators

    Vertex Pharmaceuticals Incorporated · Granted Jan 16, 2024 · Expires Jan 11, 2044

    granted

  5. US 11866446

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted

  6. US 11866450

    Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

    Vertex Pharmaceuticals Incorporated · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted

  7. US 11834441

    Substituted tetrahydrofurans as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted

  8. US 11827627

    N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted

  9. US 11813267

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted

  10. US 11807882

    Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

    Vertex Pharmaceuticals Incorporated · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  11. US 11801234

    Methods of treating APOL-1 dependent focal segmental glomerulosclerosis

    Vertex Pharmaceuticals Incorporated · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  12. US 11801313

    Materials and methods for treatment of pain related disorders

    Vertex Pharmaceuticals Incorporated · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  13. US 11773119

    Prodrugs of pyridone amides useful as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted

  14. US 11752106

    Pharmaceutical composition and administrations thereof

    Vertex Pharmaceuticals Incorporated · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted

  15. US 11673864

    Pyridone amides as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted

  16. US 11639347

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted May 2, 2023 · Expires Apr 27, 2043

    granted

  17. US 11634447

    Mannose derivatives for treating bacterial infections

    Vertex Pharmaceuticals Incorporated · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  18. US 11623924

    Modulators of alpha-1 antitrypsin

    Vertex Pharmaceuticals Incorporated · Granted Apr 11, 2023 · Expires Apr 6, 2043

    granted

  19. US 11618746

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Apr 4, 2023 · Expires Mar 30, 2043

    granted

  20. US 11613744

    Modified urokinase-type plasminogen activator polypeptides and methods of use

    Vertex Pharmaceuticals Incorporated · Granted Mar 28, 2023 · Expires Mar 23, 2043

    granted

  21. US 11603351

    Carboxamides as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Mar 14, 2023 · Expires Mar 9, 2043

    granted

  22. US 11591350

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  23. US 11578062

    Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

    Vertex Pharmaceuticals Incorporated · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted

  24. US 11572364

    Pteridinone compounds and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Feb 7, 2023 · Expires Feb 2, 2043

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.